Ng recombinant vaccinia: implications for vaccine improvement. J Exp Med. 1992; 176:169?76. [PubMed: 1377222] ten. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus- specific cytotoxic T cell epitope in EBV nuclear antigen three (EBNA 3). J Exp Med. 1990; 171:345?49. [PubMed: 1688611] 11? Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008; 82:1448?457. A feasibility trial that demonstrated safety and immunogenicity of an EBV CD8+ T-cell peptide vaccine. Although not practical for common use because of HLA restriction, it could be studied in subjects whose HLA is well characterized, for instance pretransplant candidates. [PubMed: 18032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified CD160 Protein manufacturer vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013; 73:1676?688. A thoroughly developed trial whose hypothesis is that enhanced recognition of tumor cells via their expression of EBNA antigens EBNA-1 and LMP-2 will probably be therapeutic. Security, immunogenicity, along with a dose-response MFAP4, Human (HEK293, His-Flag) impact had been demonstrated. [PubMed: 23348421] 13. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis–and what else? J Infect Dis. 2007; 196:1724?726. [PubMed: 18190249]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptCurr Opin Virol. Author manuscript; offered in PMC 2015 June 01.BalfourPage14. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) for the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987; 61:1416?1420. [PubMed: 3033269] 15. Moss DJ, Pope JH. Assay on the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972; 17:233?36. [PubMed: 4344316] 16. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity far better than antibody titers to EBV gp42 employing a speedy flow cytometry-based EBV neutralization assay. Virology. 2009; 391:249?56. [PubMed: 19584018] 17. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997; 276:2030?033. [PubMed: 9197263] 18? Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that grow to be infected with virus right after challenge. PLoS Pathog. 2011; 7:e1002308. An important study in which rhesus macques have been protected from an EBV challenge infection right after getting gp350 vaccine. [PubMed: 22028652] 19? Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic factors related with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013; 207:80?8. A prospective study demonstrating the significant illness burden of major EBV infection in EBV-na e college freshmen. Such students are perfect subjects.
